|
Back to EZorb Newsletter Index |
|
In this issue:
Letter I: From Mary O. I have been taking EZorb for over 3 months now. I used to have horrible pain in my big toe, and could not walk very well. I had several injections that only helped for a short period of time. Also had back pain, sciatica and neck pain. At the end of the second month taking EZorb, I noticed my pain was subsiding and now after three months, no pain at all. I had not had success with any other alternative substances. This one seems to do the trick. Thank you. Letter II: From Patricia H., Jasper, IN "I'm 74 years old and have been taking your EZorb and Marvlix products for many years. They are the best thing one could take. They help lower my cholesterol and help my bones." "I just had a physical recently and my doctor is so impressed. Anytime you need a testimonial I'm happy to oblige. Feel free to call me anytime. Thank you for these wonderful products!" From the Desk of EZorb Newsletter Editor:This newsletter is now read by over 120,000 subscribers worldwide. Success stories you have contributed over the years have had a great impact on many people's life. Please email your story to sharesuccess @ ezorbonline.com or simply post it at Testimonial Submit Form. Your personal information will never be revealed to the public. 2. Research News: Metformin Use Linked to Favorable COVID-19 OutcomeThe latest report from the CORONADO study reveals factors predictive of home discharge within 28 days among people with diabetes hospitalized with COVID-19, as well as those linked to mortality risk. “In addition to data on in-hospital death, we believe data on home discharge within 28 days should be reported since it is a positive result of value for both patients and physicians and it provides another perspective on COVID-19,” write the investigators in Diabetologia. A previous report from the multicenter French CORONADO study identified high BMI as a key factor associated with mortality risk within 7 days of hospitalization. The latest analysis involves a larger number of patients (n=2796), with follow-up to 28 days. They were an average age of 69.7 years, and 36.3% were women. Half (50.2%) of these patients were discharged home within 28 days of admission. In multivariate analyses, younger age was strongly associated with an increased likelihood of discharge, as was a longer duration of symptoms prior to admission. In addition, metformin use was associated with a significant 40% increased likelihood of discharge, in line with a recent study suggesting a protective effect of the medication against mortality, although only in women. Around one in five (20.6%) people died by day 28, with deaths being fairly evenly divided between the first 7 days (11.2%) and days 8-28 (9.5%). Factors predictive of discharge were also associated with an increased likelihood of survival at 28 days. Variables significantly associated with 28-day mortality risk were having microvascular complications of diabetes, being on anticoagulant treatment at baseline, and having dyspnea. Also, higher levels of liver enzymes, white blood cells, and C-reactive protein - all reflecting more severe COVID-19 - were associated with mortality risk. Glycated hemoglobin (HbA1c) was not associated with outcomes, and neither were other comorbidities including macrovascular complications. By contrast with the previous publication, BMI was not predictive of mortality. However, the researchers point to the findings from the OpenSAFELY study, which demonstrated increased mortality risk with high BMI and a “clearly graded effect” of HbA1c in data from more than 10,000 deaths related to COVID-19, and highlight the comparatively “more limited dataset” of the CORONADO study. Baseline insulin use was associated with a significantly increased 28-day mortality risk, as was use of a statin, which the researchers say is “surprising since the in-hospital use of this drug class has been recently associated with a lower risk of 28-day mortality in 13,981 patients with COVID-19 from China.” They say it is not clear whether the associations with pre-existing treatments represent “a significant negative effect or a mere indication bias” and that the statistical analyses needed to give a clearer idea are “beyond the scope of the current paper.” Original research was published in Diabetologia 2021; doi:10.1007/s00125-020-05351-w. 3. Useful LinksEZorb - Frequently Asked Questions & Answers 4. What Are Others Saying About EZorb and Marvlix?EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families
around the world. Click here to read what people say about EZorb
and Marvlix. |
|
Back to EZorb Newsletter Index |